FBR Capital Cuts Price Target After Genocea Biosciences (GNCA) Reports Disappointing GEN-004 Data
Tweet Send to a Friend
FBR Capital reiterated an Outperform rating on Genocea Biosciences (NASDAQ: GNCA), and cut the price target to $17.00 (from $20.00) ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
